City of Hope | Strategic Alliance Partners

September 05, 2019

Amrita Krishnan, MD, highlights recent research in relapsed/refractory multiple myeloma.

September 03, 2019

Michael A. Rosenzweig, MD, MS, discusses changes in the frontline setting of multiple myeloma.

September 03, 2019

David S. Snyder, MD, highlights agents currently undergoing clinical trials for polycythemia vera and myelofibrosis as well as how to most effectively treat patients using transplantation.

August 20, 2019

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate clinical professor of surgical oncology, Department of Surgery, and surgical oncologist, City of Hope, discusses data regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with metastatic colorectal cancer (mCRC).

August 16, 2019

Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses investigational approaches in peripheral T-cell lymphoma.

August 15, 2019

Vinod A. Pullarkat, MD, clinical professor of Hematology & Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses treatment strategies in transplant ineligible acute lymphoblastic leukemia (ALL).

August 14, 2019

Saul Priceman, PhD, City of Hope assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation, and his research team have received a $9.28 million award from the California Institute for Regenerative Medicine to support a chimeric antigen receptor T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.

August 14, 2019

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses mainstays of treatment in polycythemia vera (PV).

August 06, 2019

Tanya Siddiqi, MD, explains how novel agents are improving the treatment landscape for chronic lymphocytic leukemia, citing examples from the TRANSCEND CLL 004 trial.

August 05, 2019

Matthew G. Mei, MD, assistant clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses investigational CAR T-cell therapies and antibody-drug conjugates (ADCs) in Hodgkin lymphoma.

August 03, 2019

Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope, discusses the CLL14 trial, which tested venetoclax (Venclexta) plus obinutuzumab (Gazyva) versus obinutuzumab plus chlorambucil in patients with previously untreated chronic lymphocytic leukemia and coexisting conditions.

July 30, 2019

With its long-standing commitment to patients, the designation makes City of Hope the highest ranked cancer hospital in the West.

July 29, 2019

PD-L1–positive natural killer cells may prove to be another important immune effector cell for checkpoint inhibitor-based cancer immunotherapy.

July 23, 2019

Sumanta Kumar Pal, MD, an associate clinical professor, Department of Medical Oncology & Therapeutics Research, co-director, Kidney Cancer Program, and medical oncologist at City of Hope, discusses the design of the phase II SWOG 1500 trial (NCT02761057) in locally advanced or metastatic papillary renal cell carcinoma (RCC).

July 02, 2019

Mihaela C. Cristea, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discusses investigational maintenance strategies in advanced ovarian cancer.

July 01, 2019

Larry Kwak, MD, PhD, has been appointed the deputy director of City of Hope's Hematologic Malignancies and Stem Cell Transplantation Institute.

June 11, 2019

Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses the use of PARP inhibitors in prostate cancer.

June 10, 2019

Mihaela C. Cristea, MD, emphasizes the use of molecular testing over tumor testing in ovarian cancer.

June 10, 2019

Thanh H. Dellinger, MD, provides insight on the treatment of patients with newly diagnosed advanced ovarian cancer.

June 07, 2019

Mihaela C. Cristea, MD, discusses the impact of the SOLO-1 trial on current approaches to frontline maintenance therapy as well as the trials that are underway with niraparib, rucaparib, and the investigational PARP inhibitor veliparib.